/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.
/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay’s lead program includes FPI-1434, […]
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) CEO John Valliant sold 11,994 shares of Fusion Pharmaceuticals stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $6.41, for a total transaction of $76,881.54. Following the transaction, the chief executive officer now directly owns 328,130 shares in […]